Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
JUPITER NEUROSCIENCES INC (JUNS) Stock Price & Overview
NASDAQ:JUNS • US48208B2034
Current stock price
0.36 USD
-0.01 (-2.25%)
Last:
The current stock price of JUNS is 0.36 USD. Today JUNS is down by -2.25%. In the past month the price decreased by -4.31%. In the past year, price decreased by -43.75%.
JUNS Key Statistics
52-Week Range0.3062 - 3.33
Current JUNS stock price positioned within its 52-week range.
1-Month Range0.338 - 0.5
Current JUNS stock price positioned within its 1-month range.
- Market Cap
- 13.061M
- P/E
- N/A
- Fwd P/E
- 5.88
- EPS (TTM)
- -0.26
- Dividend Yield
- N/A
JUNS Stock Performance
Today
-2.25%
1 Week
-19.75%
1 Month
-4.31%
3 Months
-31.79%
Longer-term
6 Months -74.83%
1 Year -43.75%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
JUNS Stock Chart
JUNS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to JUNS. When comparing the yearly performance of all stocks, JUNS is a bad performer in the overall market: 92.23% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
JUNS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to JUNS. Both the profitability and financial health of JUNS have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
JUNS Earnings
On April 1, 2026 JUNS reported an EPS of -0.07 and a revenue of 22.00K. The company beat EPS expectations (6.16% surprise) and missed revenue expectations (-71.24% surprise).
Next Earnings DateN/A
Last Earnings DateApr 1, 2026
PeriodQ4 / 2025
EPS Reported-$0.07
Revenue Reported22K
EPS Surprise 6.16%
Revenue Surprise -71.24%
JUNS Forecast & Estimates
7 analysts have analysed JUNS and the average price target is 25.5 USD. This implies a price increase of 6983.33% is expected in the next year compared to the current price of 0.36.
For the next year, analysts expect an EPS growth of 123.81% and a revenue growth 16076.5% for JUNS
Analysts
Analysts82.86
Price Target25.5 (6983.33%)
EPS Next Y123.81%
Revenue Next Year16076.5%
JUNS Financial Highlights
Over the last trailing twelve months JUNS reported a non-GAAP Earnings per Share(EPS) of -0.26. The EPS decreased by -212.13% compared to the year before.
Income Statements
Revenue(TTM)21.80K
Net Income(TTM)-8.64M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -155.37% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-34%
Sales Q2Q%N/A
EPS 1Y (TTM)-212.13%
Revenue 1Y (TTM)N/A
JUNS Ownership
Ownership
Inst Owners4.44%
Shares36.28M
Float17.66M
Ins Owners43.61%
Short Float %0.43%
Short Ratio0.57
JUNS Industry Overview
JUNS operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.0
- Average Fwd P/E
- 19.7
- Average Debt/Equity
- 1.2
JUNS Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.34 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.92 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.79 | 271.761B | ||
| PFE | PFIZER INC | 8.79 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.1 | 118.952B | ||
| ZTS | ZOETIS INC | 16.09 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.58 | 28.582B | ||
| VTRS | VIATRIS INC | 6 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.72 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.86 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About JUNS
Company Profile
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Company Info
IPO: 2024-12-03
JUPITER NEUROSCIENCES INC
1001 North US HWY 1, Suite 504
Palm Beach Gardens FLORIDA US
Employees: 4
Phone: 15614066154
JUPITER NEUROSCIENCES INC / JUNS FAQ
What does JUPITER NEUROSCIENCES INC do?
Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company engaged in treating neuroinflammation with a current focus on CNS disorders and rare diseases. The company is headquartered in Palm Beach Gardens, Florida and currently employs 4 full-time employees. The company went IPO on 2024-12-03. The firm has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The firm has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. The company has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.
Can you provide the latest stock price for JUPITER NEUROSCIENCES INC?
The current stock price of JUNS is 0.36 USD. The price decreased by -2.25% in the last trading session.
What is the dividend status of JUPITER NEUROSCIENCES INC?
JUNS does not pay a dividend.
What is the ChartMill technical and fundamental rating of JUNS stock?
JUNS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting JUNS stock to perform?
7 analysts have analysed JUNS and the average price target is 25.5 USD. This implies a price increase of 6983.33% is expected in the next year compared to the current price of 0.36.
Can you provide the PE ratio for JUNS stock?
JUPITER NEUROSCIENCES INC (JUNS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.26).
Can you provide the market cap for JUPITER NEUROSCIENCES INC?
JUPITER NEUROSCIENCES INC (JUNS) has a market capitalization of 13.06M USD. This makes JUNS a Nano Cap stock.